Cargando…

Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer

BACKGROUND: Many studies have reported an increased risk of developing a second primary malignancy (SPM) of the breast in women treated for thyroid cancer. In this study, we investigated several potential risk factors for this association. The aim of this retrospective cohort study was to identify a...

Descripción completa

Detalles Bibliográficos
Autores principales: Consorti, Fabrizio, Di Tanna, Gianluca, Milazzo, Francesca, Antonaci, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174118/
https://www.ncbi.nlm.nih.gov/pubmed/21835042
http://dx.doi.org/10.1186/1477-7819-9-88
_version_ 1782212029257351168
author Consorti, Fabrizio
Di Tanna, Gianluca
Milazzo, Francesca
Antonaci, Alfredo
author_facet Consorti, Fabrizio
Di Tanna, Gianluca
Milazzo, Francesca
Antonaci, Alfredo
author_sort Consorti, Fabrizio
collection PubMed
description BACKGROUND: Many studies have reported an increased risk of developing a second primary malignancy (SPM) of the breast in women treated for thyroid cancer. In this study, we investigated several potential risk factors for this association. The aim of this retrospective cohort study was to identify a subgroup of women surgically treated for papillary thyroid cancer that may benefit from more careful breast cancer screening. METHODS: A total of 101 women surgically treated for papillary thyroid cancer from 1996 to 2009 with subsequent follow-up were interviewed by phone regarding personal risk factors and lifestyle habits. Only 75 questionnaires could be evaluated due to a 25.7% rate of patients not retrieved or refusing the interview. Data analysis was performed using a multivariate logistic model. RESULTS: The standardised incidence ratio (SIR) for breast cancer was 3.58 (95% IC 1.14 - 8.37). Our data suggest a protective effect of multiparity on the development of a SPM of the breast (O.R. 0.15; 95% IC 0.25 - 0.86). Significant associations were not found with other known risk factors including Body Mass Index (BMI), age at first tumour, concurrent metabolic diseases, smoking, physical activity and familiarity. CONCLUSIONS: This study confirms that a higher incidence of SPM of the breast is observed in women treated for papillary thyroid cancer. Additionally, this risk is increased by nulliparity, thus a strict breast screening program for nulliparous women treated for thyroid cancer may be advisable.
format Online
Article
Text
id pubmed-3174118
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31741182011-09-16 Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer Consorti, Fabrizio Di Tanna, Gianluca Milazzo, Francesca Antonaci, Alfredo World J Surg Oncol Research BACKGROUND: Many studies have reported an increased risk of developing a second primary malignancy (SPM) of the breast in women treated for thyroid cancer. In this study, we investigated several potential risk factors for this association. The aim of this retrospective cohort study was to identify a subgroup of women surgically treated for papillary thyroid cancer that may benefit from more careful breast cancer screening. METHODS: A total of 101 women surgically treated for papillary thyroid cancer from 1996 to 2009 with subsequent follow-up were interviewed by phone regarding personal risk factors and lifestyle habits. Only 75 questionnaires could be evaluated due to a 25.7% rate of patients not retrieved or refusing the interview. Data analysis was performed using a multivariate logistic model. RESULTS: The standardised incidence ratio (SIR) for breast cancer was 3.58 (95% IC 1.14 - 8.37). Our data suggest a protective effect of multiparity on the development of a SPM of the breast (O.R. 0.15; 95% IC 0.25 - 0.86). Significant associations were not found with other known risk factors including Body Mass Index (BMI), age at first tumour, concurrent metabolic diseases, smoking, physical activity and familiarity. CONCLUSIONS: This study confirms that a higher incidence of SPM of the breast is observed in women treated for papillary thyroid cancer. Additionally, this risk is increased by nulliparity, thus a strict breast screening program for nulliparous women treated for thyroid cancer may be advisable. BioMed Central 2011-08-12 /pmc/articles/PMC3174118/ /pubmed/21835042 http://dx.doi.org/10.1186/1477-7819-9-88 Text en Copyright ©2011 Consorti et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Consorti, Fabrizio
Di Tanna, Gianluca
Milazzo, Francesca
Antonaci, Alfredo
Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer
title Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer
title_full Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer
title_fullStr Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer
title_full_unstemmed Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer
title_short Nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer
title_sort nulliparity enhances the risk of second primary malignancy of the breast in a cohort of women treated for thyroid cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174118/
https://www.ncbi.nlm.nih.gov/pubmed/21835042
http://dx.doi.org/10.1186/1477-7819-9-88
work_keys_str_mv AT consortifabrizio nulliparityenhancestheriskofsecondprimarymalignancyofthebreastinacohortofwomentreatedforthyroidcancer
AT ditannagianluca nulliparityenhancestheriskofsecondprimarymalignancyofthebreastinacohortofwomentreatedforthyroidcancer
AT milazzofrancesca nulliparityenhancestheriskofsecondprimarymalignancyofthebreastinacohortofwomentreatedforthyroidcancer
AT antonacialfredo nulliparityenhancestheriskofsecondprimarymalignancyofthebreastinacohortofwomentreatedforthyroidcancer